153 related articles for article (PubMed ID: 10398105)
1. In situ expression patterns of melanoma-inhibiting activity (MIA) in melanomas and breast cancers.
Bosserhoff AK; Moser M; Hein R; Landthaler M; Buettner R
J Pathol; 1999 Mar; 187(4):446-54. PubMed ID: 10398105
[TBL] [Abstract][Full Text] [Related]
2. Detection of melanoma cells in the blood of melanoma patients by melanoma-inhibitory activity (MIA) reverse transcription-PCR.
Mühlbauer M; Langenbach N; Stolz W; Hein R; Landthaler M; Buettner R; Bosserhoff AK
Clin Cancer Res; 1999 May; 5(5):1099-105. PubMed ID: 10353744
[TBL] [Abstract][Full Text] [Related]
3. Melanoma inhibitor of apoptosis protein is expressed differentially in melanoma and melanocytic naevus, but similarly in primary and metastatic melanomas.
Gong J; Chen N; Zhou Q; Yang B; Wang Y; Wang X
J Clin Pathol; 2005 Oct; 58(10):1081-5. PubMed ID: 16189155
[TBL] [Abstract][Full Text] [Related]
4. Melanoma-inhibiting activity (MIA/CD-RAP) is expressed in a variety of malignant tumors of mainly neuroectodermal origin.
Hau P; Apfel R; Wiese P; Tschertner I; Blesch A; Bogdahn U
Anticancer Res; 2002; 22(2A):577-83. PubMed ID: 12014625
[TBL] [Abstract][Full Text] [Related]
5. Micro-anatomy related antigen expression in melanocytic lesions.
Meije CB; Mooi WJ; Le Poole IC; Van Muijen GN; Das PK
J Pathol; 2000 Apr; 190(5):572-8. PubMed ID: 10727983
[TBL] [Abstract][Full Text] [Related]
6. Cadherin expression in melanocytic naevi and malignant melanomas.
Cowley GP; Smith ME
J Pathol; 1996 Jun; 179(2):183-7. PubMed ID: 8758211
[TBL] [Abstract][Full Text] [Related]
7. Expression patterns of S100 proteins in melanocytes and melanocytic lesions.
Petersson S; Shubbar E; Enerbäck L; Enerbäck C
Melanoma Res; 2009 Aug; 19(4):215-25. PubMed ID: 19521263
[TBL] [Abstract][Full Text] [Related]
8. Cytokeratin expression in malignant melanoma: potential application of in-situ hybridization analysis of mRNA.
Chen N; Gong J; Chen X; Xu M; Huang Y; Wang L; Geng N; Zhou Q
Melanoma Res; 2009 Apr; 19(2):87-93. PubMed ID: 19190520
[TBL] [Abstract][Full Text] [Related]
9. Gene expression patterns in melanocytic cells: candidate markers for early stage and malignant transformation.
Meije CB; Hakvoort TB; Swart GW; Westerhof W; Lamers WH; Das PK
J Pathol; 2002 Jan; 196(1):51-8. PubMed ID: 11748642
[TBL] [Abstract][Full Text] [Related]
10. Melanoma-inhibiting activity, a novel serum marker for progression of malignant melanoma.
Bosserhoff AK; Kaufmann M; Kaluza B; Bartke I; Zirngibl H; Hein R; Stolz W; Buettner R
Cancer Res; 1997 Aug; 57(15):3149-53. PubMed ID: 9242442
[TBL] [Abstract][Full Text] [Related]
11. Inducible nitric oxide synthase expression in benign and malignant cutaneous melanocytic lesions.
Massi D; Franchi A; Sardi I; Magnelli L; Paglierani M; Borgognoni L; Maria Reali U; Santucci M
J Pathol; 2001 Jun; 194(2):194-200. PubMed ID: 11400148
[TBL] [Abstract][Full Text] [Related]
12. Overexpression of Lerk-5/Eplg5 messenger RNA: a novel marker for increased tumorigenicity and metastatic potential in human malignant melanomas.
Vogt T; Stolz W; Welsh J; Jung B; Kerbel RS; Kobayashi H; Landthaler M; McClelland M
Clin Cancer Res; 1998 Mar; 4(3):791-7. PubMed ID: 9533549
[TBL] [Abstract][Full Text] [Related]
13. Macrophage migration inhibitory factor protein and mRNA expression in cutaneous melanocytic tumours.
Miracco C; De Nisi MC; Arcuri F; Cosci E; Pacenti L; Toscano M; Lalinga AV; Biagioli M; Rubegni P; Vatti R; Maellaro E; Del Bello B; Massi D; Luzi P; Tosi P
Int J Oncol; 2006 Feb; 28(2):345-52. PubMed ID: 16391788
[TBL] [Abstract][Full Text] [Related]
14. Patterns of melastatin mRNA expression in melanocytic tumors.
Deeds J; Cronin F; Duncan LM
Hum Pathol; 2000 Nov; 31(11):1346-56. PubMed ID: 11112208
[TBL] [Abstract][Full Text] [Related]
15. Melanoma-inhibiting activity (MIA) mRNA is not exclusively transcribed in melanoma cells: low levels of MIA mRNA are present in various cell types and in peripheral blood.
de Vries TJ; Fourkour A; Punt CJ; Diepstra H; Ruiter DJ; van Muijen GN
Br J Cancer; 1999 Nov; 81(6):1066-70. PubMed ID: 10576666
[TBL] [Abstract][Full Text] [Related]
16. Prognostic relevance of P-cadherin expression in melanocytic skin tumours analysed by high-throughput tissue microarrays.
Bauer R; Wild PJ; Meyer S; Bataille F; Pauer A; Klinkhammer-Schalke M; Hofstaedter F; Bosserhoff AK
J Clin Pathol; 2006 Jul; 59(7):699-705. PubMed ID: 16565225
[TBL] [Abstract][Full Text] [Related]
17. Expression of melanoma inhibitory activity in melanoma and nonmelanoma tissue specimens.
Perez RP; Zhang P; Bosserhoff AK; Buettner R; Abu-Hadid M
Hum Pathol; 2000 Nov; 31(11):1381-8. PubMed ID: 11112213
[TBL] [Abstract][Full Text] [Related]
18. Expression of interleukin-8 detected by in situ hybridization correlates with worse prognosis in primary cutaneous melanoma.
Nürnberg W; Tobias D; Otto F; Henz BM; Schadendorf D
J Pathol; 1999 Dec; 189(4):546-51. PubMed ID: 10629556
[TBL] [Abstract][Full Text] [Related]
19. Expression and activation of matrix metalloproteinase-2 (MMP-2) and its co-localization with membrane-type 1 matrix metalloproteinase (MT1-MMP) correlate with melanoma progression.
Hofmann UB; Westphal JR; Zendman AJ; Becker JC; Ruiter DJ; van Muijen GN
J Pathol; 2000 Jul; 191(3):245-56. PubMed ID: 10878545
[TBL] [Abstract][Full Text] [Related]
20. MIA, a novel serum marker for progression of malignant melanoma.
Bosserhoff AK; Lederer M; Kaufmann M; Hein R; Stolz W; Apfel R; Bogdahn U; Buettner R
Anticancer Res; 1999; 19(4A):2691-3. PubMed ID: 10470221
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
